Literature DB >> 18005986

Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.

Jeffrey E Lee1, Ana Kuehne, Dafna M Abelson, Marnie L Fusco, Mary Kate Hart, Erica Ollmann Saphire.   

Abstract

13F6-1-2 is a murine monoclonal antibody that recognizes the heavily glycosylated mucin-like domain of the Ebola virus virion-attached glycoprotein (GP) and protects animals against lethal viral challenge. Here we present the crystal structure, at 2.0 A, of 13F6-1-2 in complex with its Ebola virus GP peptide epitope. The GP peptide binds in an extended conformation, anchored primarily by interactions with the heavy chain. Two GP residues, Gln P406 and Arg P409, make extensive side-chain hydrogen bond and electrostatic interactions with the antibody and are likely critical for recognition and affinity. The 13F6-1-2 antibody utilizes a rare V lambda(x) light chain. The three light-chain complementarity-determining regions do not adopt canonical conformations and represent new classes of structures distinct from V kappa and other V lambda light chains. In addition, although V lambda(x) had been thought to confer specificity, all light-chain contacts are mediated through germ-line-encoded residues. This structure of an antibody that protects against the Ebola virus now provides a framework for humanization and development of a postexposure immunotherapeutic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005986      PMCID: PMC2173910          DOI: 10.1016/j.jmb.2007.10.017

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  47 in total

1.  Flexible structure alignment by chaining aligned fragment pairs allowing twists.

Authors:  Yuzhen Ye; Adam Godzik
Journal:  Bioinformatics       Date:  2003-10       Impact factor: 6.937

2.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Structure       Date:  2004-02       Impact factor: 5.006

3.  Mouse V lambda x gene sequence generates no junctional diversity and is conserved in mammalian species.

Authors:  P Sanchez; P N Marche; D Rueff-Juy; P A Cazenave
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

4.  Canonical structures for the hypervariable regions of immunoglobulins.

Authors:  C Chothia; A M Lesk
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

5.  Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire.

Authors:  K M Johnson; J V Lange; P A Webb; F A Murphy
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

6.  A new variable region in mouse immunoglobulin lambda light chains.

Authors:  P Sanchez; P A Cazenave
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

7.  A new V gene expressed in lambda-2 light chains of the mouse.

Authors:  R Dildrop; A Gause; W Müller; K Rajewsky
Journal:  Eur J Immunol       Date:  1987-05       Impact factor: 5.532

8.  Release of viral glycoproteins during Ebola virus infection.

Authors:  V E Volchkov; V A Volchkova; W Slenczka; H D Klenk; H Feldmann
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

9.  Hydrogen bonding and biological specificity analysed by protein engineering.

Authors:  A R Fersht; J P Shi; J Knill-Jones; D M Lowe; A J Wilkinson; D M Blow; P Brick; P Carter; M M Waye; G Winter
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

10.  Structure of a third murine immunoglobulin lambda light chain variable region that is expressed in laboratory mice.

Authors:  P Sanchez; P N Marche; C Le Guern; P A Cazenave
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

View more
  36 in total

1.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Authors:  Daniel Olal; Ana I Kuehne; Shridhar Bale; Peter Halfmann; Takao Hashiguchi; Marnie L Fusco; Jeffrey E Lee; Liam B King; Yoshihiro Kawaoka; John M Dye; Erica Ollmann Saphire
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

4.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.

Authors:  Edgar Davidson; Christopher Bryan; Rachel H Fong; Trevor Barnes; Jennifer M Pfaff; Manu Mabila; Joseph B Rucker; Benjamin J Doranz
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

5.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Authors:  John Misasi; Morgan S A Gilman; Masaru Kanekiyo; Miao Gui; Alberto Cagigi; Sabue Mulangu; Davide Corti; Julie E Ledgerwood; Antonio Lanzavecchia; James Cunningham; Jean Jacques Muyembe-Tamfun; Ulrich Baxa; Barney S Graham; Ye Xiang; Nancy J Sullivan; Jason S McLellan
Journal:  Science       Date:  2016-02-25       Impact factor: 47.728

6.  Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Authors:  Anna Z Wec; Andrew S Herbert; Charles D Murin; Elisabeth K Nyakatura; Dafna M Abelson; J Maximilian Fels; Shihua He; Rebekah M James; Marc-Antoine de La Vega; Wenjun Zhu; Russell R Bakken; Eileen Goodwin; Hannah L Turner; Rohit K Jangra; Larry Zeitlin; Xiangguo Qiu; Jonathan R Lai; Laura M Walker; Andrew B Ward; John M Dye; Kartik Chandran; Zachary A Bornholdt
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

7.  Structures of protective antibodies reveal sites of vulnerability on Ebola virus.

Authors:  Charles D Murin; Marnie L Fusco; Zachary A Bornholdt; Xiangguo Qiu; Gene G Olinger; Larry Zeitlin; Gary P Kobinger; Andrew B Ward; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

8.  Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.

Authors:  Joseph E Blaney; Christoph Wirblich; Amy B Papaneri; Reed F Johnson; Carey J Myers; Terry L Juelich; Michael R Holbrook; Alexander N Freiberg; John G Bernbaum; Peter B Jahrling; Jason Paragas; Matthias J Schnell
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

9.  Dissociation of the Dimer of the Intrinsically Disordered Domain of RNase Y upon Antibody Binding.

Authors:  Pierre Hardouin; Christophe Velours; Charles Bou-Nader; Nadine Assrir; Soumaya Laalami; Harald Putzer; Dominique Durand; Béatrice Golinelli-Pimpaneau
Journal:  Biophys J       Date:  2018-10-26       Impact factor: 4.033

10.  Antibodies that bind complex glycosaminoglycans accumulate in the Golgi.

Authors:  Marko Radic; Martin G Weigert; Salar N Khan; Jiong Han; Olga Kalinina; Eline T Luning Prak
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.